Ware

Revolutionary anti-cancer treatment, also available in Romania

Revolutionary anti-cancer treatment, also available in Romania

Just three months after the European launch, the pharmaceutical company F.Hoffmann - La Roche announces the registration in Romania of the latest form of therapy for the treatment of colorectal cancer - Avastin®. The product is the first drug that inhibits angiogenesis - development of blood vessels that nourish the tumor tissues. Product registration for other cancers will take place in the coming months.

Just three months after the European launch, the pharmaceutical company F.Hoffmann - La Roche announces the registration in Romania of the latest form of therapy for the treatment of colorectal cancer - Avastin®. The product is the first drug that inhibits angiogenesis - development of blood vessels that nourish the tumor tissues. Product registration for other cancers will take place in the coming months.
"The Hoffmann - La Roche company is consistent in introducing to the Romanian market the latest forms of therapy, which respond to vital treatment needs, such as cancer, AIDS, the area of ​​viral hepatitis and transplantation. This medicine, whose registration we have we are pleased to announce it today in Romania as well, it represents a revolution in medicine, offering new life expectancy for cancer patients, "said Dan Zamonea, General Manager, Roche Romania.


"Avastin® confirms the results of research started in 1971 when Professor Jdah Folkman of Harvard Medical School launched the theory that cancer cells can be combated by disrupting the developmental mechanisms of the blood vessels that nourish these cells, a process called scientifically angiogenesis. to live, the cancer cells need blood supply. If this blood supply is interrupted, the cancer cells do not develop anymore. This is in fact the principle on which the mechanism of action of bevacizumab is based, "said Prof. Dr. Rodica Anghel, General Director of the Bucharest Oncological Institute.
The first results of the research appeared in 2001, and the subsequent results confirmed that angeogenesis theory is an effective strategy for the treatment of cancerous diseases. Cancer cells, which have a much faster growth and multiplication rate than normal cells in the body, release a growth factor called VEGF, to create new blood vessels to provide them with increased oxygen and nutrient needs. Avastin® inhibits this VEGF factor, thus blocking the formation of blood vessels initiated by cancer cells and leading to regression of newly formed vessels.
Results of the latest Avastin® efficacy study (bevacizumab) in cancer treatment, funded by the National Cancer Institute (NCI) of the National Institute for Health (NIH) and conducted by a team of researchers from the Eastern Cooperative Oncology Group (ECOG), have highlighted significant benefits in lung cancer therapy with Avastin® and colon cancer - the most common types of cancer found worldwide, the drug receiving approval from the US and European authorities in the emergency procedure. Treatment with bevacizumab In colorectal cancer, life expectancy increases by 67% compared to traditional chemotherapy-only treatment.
The study also showed that bevacizumab therapy doubles the life expectancy of untreated metastatic breast cancer patients compared to chemotherapy-only treatment. The study was presented at the end of May as part of the annual meeting of ASCO - American Society of Clinical Oncology held in Orlando, USA.
Breast cancer represents 1/5 of the total number of cancer cases in women, with 1 million new cases occurring worldwide each year and a mortality rate of 410,000.
Lung cancer is the most common form of cancer in the world, with 1.3 million new cases occurring each year and over 1 million deaths from this disease.
The NCI-supported study conducted by ECOG - an independent body whose mission is to identify effective cancer treatment solutions - comprised three parts. The first part aimed to evaluate the efficacy of bevacizumab in breast cancer and was performed on a sample of 722 patients who received paclitaxel in combination or without bevacizumab.
The second part of the study aimed to evaluate the effectiveness of Avastin® in the treatment of lung cancer and included 878 patients with advanced forms of NSCLC - small cell lung cancer. The patients received chemotherapy treatment, in combination or without bevacizumab, given in 4-6 cures, every 3 weeks.
Avastin® is the first drug that inhibits angiogenesis - the development of blood vessels that nourish tumor tissues. Avastin® works by inhibiting a named protein VEGF (Vascular Endothelial Growth Factor), which supports angiogenesis, thus intervening in the process of angiogenesis and preventing the replication of cancer cells. In Europe, Avastin® is approved as a first-line drug for patients with metastatic carcinoma of the colon or rectal, in combination with chemotherapy. In the United States, Avastin® has received emergency approval from the US Food and Drug Administration (FDA). F.Hoffmann Company - La Roche with its partner Genentech - world leader in biotechnology - is continuing to study the potential clinical benefits of Avastin® in the treatment of pancreatic, ovarian and kidney cancer and an estimated 15,000 other patients in the coming period will be included in these clinical trials. Additional information about Avastin® and cancer - www.health-kiosk.ch